TriSalus Life Sciences, Inc. (TLSIW) Aandelenanalyse

Bedrijfsoverzicht

TriSalus Life Sciences, Inc. is primarily engaged in the research, development, and commercialization of a proprietary drug delivery technology platform alongside immuno-oncology therapeutics. The specific focus of this operational model is to improve patient outcomes for individuals suffering from difficult-to-treat liver and pancreatic cancers within the United States. Although specific sector and industry classifications are not currently assigned to the entity in available public records, the company operates as a biotechnology firm with a specialized niche in oncology treatments. The company's scale is reflected by a market capitalization that is not disclosed, an annual trailing twelve-month revenue of $45.15M, and an employee base of 102 individuals. These financial figures suggest that the organization maintains a mid-stage profile typical of biotechnology entities focused on high-risk R&D, where revenue generation is often secondary to clinical advancement. The absence of a disclosed market cap in the current data indicates that valuation is likely driven by pipeline potential rather than established cash flow generation. The revenue of $45.15M provides a tangible baseline for operational scale, while the workforce size of 102 employees points to a lean organizational structure designed to maximize resource efficiency during the development phase.

Financiële gezondheid

The company reported a revenue of $45.15M for the trailing twelve-month period, yet this was accompanied by a net income of $-69,690,000 and an EBITDA of $-26,320,000. The substantial gap between the positive revenue of $45.15M and the negative net income reveals a cost structure where expenses significantly outweigh operational earnings, a common characteristic in pre-commercialization biotechnology phases. Free cash flow stands at $-8,759,250, which indicates that the company is burning cash to fund its operations and development activities, thereby limiting its immediate financial flexibility without external capital injections. Despite the negative operating income, the gross margin remains robust at 84.6%, indicating that the cost of goods sold is relatively low compared to the revenue generated, likely due to the nature of the drug delivery platform. However, the operating margin is negative at -24.8%, and the profit margin is deeply negative at -86.9%, highlighting the heavy overhead costs associated with research, development, and administrative functions. The balance sheet shows a cash position of $20.44M against total debt of $34.44M, creating a net cash deficit, while the debt-to-equity ratio is not available in the provided data. This leverage situation, where debt exceeds cash, suggests a capital structure that relies on future fundraising to meet obligations, rather than a conservative, cash-rich stance. Liquidity is supported by a current ratio of 2.80, which indicates that the company holds sufficient current assets to cover its short-term liabilities nearly three times over. Return on Equity is not available due to the lack of equity data, but the return on assets is -56.8%, which reveals that the management's current asset utilization is generating significant losses relative to the total asset base.

Waarderingsbeoordeling

Trailing P/E and forward P/E ratios are both listed as N/A, which implies that the company does not generate positive earnings required to calculate these standard metrics, and thus no earnings trajectory can be inferred from these specific ratios. The price-to-book ratio is -1.61, a negative figure that indicates the market capitalization is less than the book value, often seen in unprofitable biotech firms where the asset base is heavily weighted towards intangible research assets rather than physical inventory. Neither the price-to-sales ratio nor the EV/EBITDA ratio are available for calculation due to the negative earnings and lack of enterprise value data in the current facts. The stock has traded within a 52-week range between a low of $0.80 and a high of $5.00, with the current trading position relative to this range dependent on the real-time price which is not provided, but the historical volatility is significant. The beta value is 0.54, which indicates that the stock price is expected to be less volatile than the broader market, moving approximately half as much as the market index during periods of fluctuation. This lower beta suggests that while the stock may offer higher potential returns due to its growth profile, it also carries specific idiosyncratic risks rather than broad market systemic risks.

Growth & Income

Revenue growth year-over-year is reported at 59.8%, demonstrating a strong expansion in top-line sales, while earnings growth is N/A due to the company's current losses. Since the earnings growth is not positive, the earnings are effectively growing slower than revenue in a traditional sense, as the net income remains negative, implying that top-line expansion has not yet translated into profitability. The company does not pay dividends, as indicated by the N/A status for both dividend yield and payout ratio, meaning that no portion of earnings is distributed to shareholders. Instead, the company reinvests its limited capital and any generated revenue back into the research, development, and commercialization of its immuno-oncology therapeutics to fuel future growth. The overall growth and income profile is characterized by high revenue expansion rates coupled with a complete absence of dividend income and current profitability, typical of early-stage biotechnology companies focused on long-term market capture rather than immediate shareholder returns.